Pegvisomant (Somavert®) conjugate (Pfizer) is used to treat acromegaly by preventing human growth hormone (hGH) binding to its receptor, because this binding activates the signal pathways that lead to IGF-1 generation. The gene discussed is GH1; the disease is acromegaly.